PURPOSE: Cancer treatment can profoundly impact the patient's quality of life (QOL). It has been well documented that there are gender differences in the symptoms associated with cancer treatment. This study explores the impact of gender on QOL for patients with newly diagnosed advanced cancer. METHODS: A randomized, controlled clinical trial in patients receiving radiotherapy for advanced cancer demonstrated maintenance of QOL with a six session multidisciplinary structured intervention compared to controls. This current study reports the gender differences in that trial. Outcome measures included the functional assessment of cancer therapy-general (FACT-G), linear analog self-assessment (LASA), and profile of mood states (POMS) at baseline and weeks 4, 27, and 52. Kruskal-Wallis was used to compare QOL scores. RESULTS:One hundred thirty-one patients (45 women and 86 men, mean age 58.7) participated in the clinical trial. At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05). Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02). At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009). By week 52, there were no statistically significant gender differences in any of the QOL measures. CONCLUSIONS: Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer, suggesting that early interventions can be tailored for each gender.
RCT Entities:
PURPOSE:Cancer treatment can profoundly impact the patient's quality of life (QOL). It has been well documented that there are gender differences in the symptoms associated with cancer treatment. This study explores the impact of gender on QOL for patients with newly diagnosed advanced cancer. METHODS: A randomized, controlled clinical trial in patients receiving radiotherapy for advanced cancer demonstrated maintenance of QOL with a six session multidisciplinary structured intervention compared to controls. This current study reports the gender differences in that trial. Outcome measures included the functional assessment of cancer therapy-general (FACT-G), linear analog self-assessment (LASA), and profile of mood states (POMS) at baseline and weeks 4, 27, and 52. Kruskal-Wallis was used to compare QOL scores. RESULTS: One hundred thirty-one patients (45 women and 86 men, mean age 58.7) participated in the clinical trial. At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASAfatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05). Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02). At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009). By week 52, there were no statistically significant gender differences in any of the QOL measures. CONCLUSIONS: Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer, suggesting that early interventions can be tailored for each gender.
Authors: Jeff A Sloan; Marlene H Frost; Rick Berzon; Amylou Dueck; Gordon Guyatt; Carol Moinpour; Mirjam Sprangers; Carol Ferrans; David Cella Journal: Support Care Cancer Date: 2006-06-23 Impact factor: 3.603
Authors: Laurel L Northouse; Darlene W Mood; Ann Schafenacker; Gregory Kalemkerian; Mark Zalupski; Patricia LoRusso; Daniel F Hayes; Maha Hussain; John Ruckdeschel; A Mark Fendrick; Peter C Trask; David L Ronis; Trace Kershaw Journal: Psychooncology Date: 2012-01-31 Impact factor: 3.894
Authors: Matthew M Clark; Teresa A Rummans; Pamela J Atherton; Andrea L Cheville; Mary E Johnson; Marlene H Frost; Janis J Miller; Jeff A Sloan; Karen M Graszer; Jean G Haas; Jean M Hanson; Yolanda I Garces; Katherine M Piderman; Maria I Lapid; Pamela J Netzel; Jarrett W Richardson; Paul D Brown Journal: Cancer Date: 2012-08-28 Impact factor: 6.860
Authors: Teresa A Rummans; Matthew M Clark; Jeff A Sloan; Marlene H Frost; John Michael Bostwick; Pamela J Atherton; Mary E Johnson; Gail Gamble; Jarrett Richardson; Paul Brown; James Martensen; Janis Miller; Katherine Piderman; Mashele Huschka; Jean Girardi; Jean Hanson Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Christian E Schmidt; Beate Bestmann; Thomas Küchler; Walter E Longo; Volker Rohde; Bernd Kremer Journal: World J Surg Date: 2005-12 Impact factor: 3.352
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Dona E C Locke; Paul A Decker; Jeff A Sloan; Paul D Brown; James F Malec; Matthew M Clark; Teresa A Rummans; Karla V Ballman; Paul L Schaefer; Jan C Buckner Journal: J Pain Symptom Manage Date: 2007-08-20 Impact factor: 3.612
Authors: Mi Hyang Um; Mi Youn Choi; Song Mi Lee; Ik Jae Lee; Chang Geol Lee; Yoo Kyoung Park Journal: Support Care Cancer Date: 2014-06-07 Impact factor: 3.603
Authors: Ryan D Nipp; Joseph A Greer; Areej El-Jawahri; Lara Traeger; Emily R Gallagher; Elyse R Park; Vicki A Jackson; William F Pirl; Jennifer S Temel Journal: Oncologist Date: 2015-11-30